文献速递呼吸危重症与机械通气

间充质基质细胞联合ECMO治疗ARDS的绵羊随机对照试验

Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

该研究在14只绵羊中建立ARDS并行静脉-静脉ECMO,随机给予支气管内人诱导多能干细胞来源间充质基质细胞或载体对照,监测24小时。hMSC未改善氧合,但减轻肺损伤评分和BAL IL-8,降低升压药累积需求;然而跨膜氧合器压力梯度升高,伴更多肺动脉血栓和氧合器纤维上黏附的hMSC。结论不推荐在静脉-静脉ECMO期间安全使用hMSC。

要点

  • 支气管内hMSC未改善ARDS绵羊ECMO期间的氧合。
  • hMSC降低肺损伤评分和BAL IL-8,并减少升压药累积需求。
  • hMSC导致氧合器跨膜压力梯度升高及更多肺动脉血栓。

核心结论

  • 在ARDS合并静脉-静脉ECMO的绵羊模型中,支气管内hMSC治疗可损害膜氧合器功能且不改善氧合。
  • 这些数据不支持在静脉-静脉ECMO期间安全使用hMSC。

研究设计与样本

  • 随机对照动物实验,14只绵羊诱导ARDS后建立静脉-静脉ECMO。
  • 随机接受支气管内诱导多能干细胞来源人MSC(n=7)或无细胞载体对照(n=7)。
  • ECMO期间采用低潮气量通气策略及程序化血流动力学支持,监测支持24小时。

主要发现

  • hMSC未改善氧合(PaO2/FiO2平均差=-146 mm Hg;P=0.076)或肺功能。
  • 肺损伤评分平均差=-0.07(P=0.04),BAL IL-8降低。
  • hMSC组升压药累积需求显著降低。
  • hMSC组跨膜氧合器压力梯度显著升高,伴更多肺动脉血栓和氧合器纤维上黏附的hMSC。

临床怎么用

  • 当前证据不支持在静脉-静脉ECMO期间使用支气管内hMSC治疗ARDS。
  • 需警惕hMSC对膜氧合器功能和肺血管血栓的影响。

局限性

  • 研究为绵羊模型,样本量14只,结果外推至临床需谨慎。
  • 仅评估支气管内给药途径和24小时观察期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Mesenchymal stromal cell (MSC) therapy is a promising intervention for acute respiratory distress syndrome (ARDS), although trials to date have not investigated its use alongside extracorporeal membrane oxygenation (ECMO). Recent preclinical studies have suggested that combining these interventions may attenuate the efficacy of ECMO.Objectives: To determine the safety and efficacy of MSC therapy in a model of ARDS and ECMO.Methods: ARDS was induced in 14 sheep, after which they were established on venovenous ECMO. Subsequently, they received either endobronchial induced pluripotent stem cell-derived human MSCs (hMSCs) (n = 7) or cell-free carrier vehicle (vehicle control; n = 7). During ECMO, a low Vt ventilation strategy was employed in addition to protocolized hemodynamic support. Animals were monitored and supported for 24 hours. Lung tissue, bronchoalveolar fluid, and plasma were analyzed, in addition to continuous respiratory and hemodynamic monitoring.Measurements and Main Results: The administration of hMSCs did not improve oxygenation (PaO2/FiO2 mean difference = -146 mm Hg; P = 0.076) or pulmonary function. However, histological evidence of lung injury (lung injury score mean difference = -0.07; P = 0.04) and BAL IL-8 were reduced. In addition, hMSC-treated animals had a significantly lower cumulative requirement for vasopressor. Despite endobronchial administration, animals treated with hMSCs had a significant elevation in transmembrane oxygenator pressure gradients. This was accompanied by more pulmonary artery thromboses and adherent hMSCs found on explanted oxygenator fibers.Conclusions: Endobronchial hMSC therapy in an ovine model of ARDS and ECMO can impair membrane oxygenator function and does not improve oxygenation. These data do not recommend the safe use of hMSCs during venovenous ECMO.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Millar JE, Bartnikowski N, Passmore MR, et al. Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep. Am J Respir Crit Care Med. 2020. PMID: 32293914. doi:10.1164/rccm.201911-2143OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。